

# **United States**

## **2021 CANNABIS REPORT**

**SEPTEMBER 2022**



**UNIVERSITY OF  
WATERLOO**

# Forward

The International Cannabis Policy Study is an international research collaboration designed to examine cannabis policy and public health impact. The project started in 2018 and includes annual population-based surveys in Canada and the United States (since 2018), as well as Australia and New Zealand (since 2021).

The current report summarizes findings among respondents from the United States for the 2021 survey, with comparisons to previous years. Additional details are available upon request.

Visit the study website for more information:  
[www.cannabisproject.ca](http://www.cannabisproject.ca).



## **FUNDING**

FUNDING FOR THE ICPS PROJECT WAS PROVIDED BY A CANADIAN INSTITUTES OF HEALTH (CIHR) PROJECT GRANT AND A CIHR PARTNERSHIPS FOR CANNABIS POLICY EVALUATION TEAM GRANT. ADDITIONAL FUNDING WAS PROVIDED BY PROVINCIAL AND STATE-LEVEL HEALTH AND REGULATORY AGENCIES.

## **ETHICS CLEARANCE**

THE PROJECT HAS BEEN REVIEWED BY AND RECEIVED ETHICS CLEARANCE THROUGH A UNIVERSITY OF WATERLOO RESEARCH ETHICS COMMITTEE (ORE#31330).

## **SUGGESTED CITATION**

HAMMOND D, CORSETTI D, GOODMAN S, IRANIPARAST M, DANH HONG D, BURKHALTER R ON BEHALF OF THE ICPS RESEARCH TEAM. INTERNATIONAL CANNABIS POLICY STUDY – UNITED STATES 2021 SUMMARY. SEPT 2022.

## **CONTACT**

DAVID HAMMOND PhD  
PROFESSOR  
SCHOOL OF PUBLIC HEALTH SCIENCES  
UNIVERSITY OF WATERLOO  
DHAMMOND@UWATERLOO.CA  
519 888 4567 EXT. 46462  
[WWW.CANNABISPROJECT.CA](http://WWW.CANNABISPROJECT.CA)



# Methods

## OVERVIEW

The International Cannabis Policy Study is a repeat cross-sectional survey conducted annually in the United States and Canada (since 2018), as well as Australia and New Zealand (since 2021) to examine trends in cannabis. This report summarizes key indicators from the 2021 ICPS survey in the United States from September 14 to November 8, 2021.

## SAMPLE

Respondents were aged 16–65 years and were recruited through the Nielsen Consumer Insights Global Panel. The analytic sample for 2021 comprised 52,938 respondents in Canada (n= 16,952), the United States (n= 30,081), Australia (2,925) and New Zealand (2,980). The results in the current report focus on the subsample of 107,572 respondents from the United States who participated in the 2018 (n= 17,112), 2019 (n= 30,479), 2020 (n= 29,900), and 2021 (n= 30,081) surveys.

## SURVEY

The survey covers the following content areas:

- prevalence and patterns of cannabis use;
- cannabis purchasing and price;
- cannabis consumption and modes of use;
- commercial retail environment;
- risk behaviours;
- cannabis knowledge, perceptions of risk and social norms;

- exposure to health warnings and public educational campaigns;
- exposure to cannabis marketing and branding;
- substance use and other risk behaviours; and
- socio-demographics and socio-economic status.

## DATA ANALYSIS

Post-stratification survey weights were created using age-by-sex-by-state, ethnicity-by-census division, education-by-state, and age-by-smoking status groups. All estimates in the current report are weighted and rescaled to the original sample size within each state.

Comparisons are provided between the ‘overall’ national estimates, as well as by legal status of cannabis at the state level. In the current report, the term ‘legal’ refers to states that had legalized non-medical cannabis for adult use at the time of data collection in each year. ‘Medical’ refers to states that had legalized medical but not non-medical adult use cannabis at the time of data collection. ‘Illegal’ refers to all other states.

## TECHNICAL REPORT

The survey and technical report are available at:

[www.cannabisproject.ca/methods](http://www.cannabisproject.ca/methods).

The technical report includes detailed information on methodology and survey weighting.




# Sample profile

## United States


	2018 n=17,112	2019 n=30,479	2020 n=29,900	2021 n=30,081
<b>Sex</b>				
Female	8,586	15,290	14,995	15,080
Male	8,526	15,189	14,905	15,001
<b>Age group</b>				
16-20	2,738	3,772	4,030	3,439
21-30	2,214	5,373	5,032	5,374
31-45	5,351	9,387	9,162	9,612
46-55	3,505	6,012	5,808	5,729
56-65	3,304	5,935	5,869	5,928
<b>Ethnicity</b>				
White	13,068	23,158	22,655	22,730
Am. Indian or Alaskan Native	140	384	288	324
Asian	648	1,207	1,368	1,132
Black or African American	2,335	4,201	4,148	4,183
Native Hawaiian or Pac Islander	34	105	110	129
Other/2+ races/Unstated	887	1,424	1,331	1,583
Hispanic origin (asked separately)	1,493	3,788	3,391	4,063
<b>Education level</b>				
<High school	2,470	3,146	2,900	3,106
High school	3,193	6,689	6,889	6,783
Some college	6,691	11,481	10,946	10,922
Bachelor's degree	4,702	9,039	8,916	9,012
<b>Income adequacy</b>				
Very difficult	1,572	3,200	2,618	3,065
Difficult	3,696	7,013	5,472	5,613
Neither easy nor difficult	5,421	10,075	10,416	9,824
Easy	3,796	5,854	6,268	6,176
Very easy	2,232	3,481	3,958	4,089

# Cannabis prevalence 2021


## Past 12 months Cannabis use



## Past month Cannabis use




## Daily / near daily Cannabis use




# Trends in cannabis prevalence

—●— Past 12 months   
 —●— Monthly   
 —●— Daily/near daily


**US total** n=107,572




**Illegal states** n=17,942




**Medical states** n=24,695




**Legal states** n=64,935



# Cannabis prevalence 2021



## By sex







# Cannabis prevalence 2021

## By age


Past 12 months



Monthly




Daily/almost daily




## By education

Past 12 months



Monthly



Daily/almost daily




# Medical authorization

Overall, 1 in 3 past 12-month cannabis consumers in the US reported that their cannabis consumption was only for medical purposes, an increase since 2019.


## Percent of consumers who self-identify as a medical marijuana user

% 'YES', PAST 12-MONTH CONSUMERS N=29,617



## Percent of consumers who self-identify as a medical marijuana user

% 'YES', PAST 12-MONTH CONSUMERS, 2021, N=10,361




# Medical authorization

Over 1 in 4 past 12-month cannabis consumers had 'ever' asked a health professional for a recommendation for medical cannabis. Among those who had asked, almost 4 in 10 had ever been refused.


## Have you ever asked a licensed health professional for a recommendation to use medical marijuana?

% 'YES', PAST 12-MONTH CONSUMERS, 2021, N=10,367



## Have you ever been refused a recommendation for medical marijuana?

% 'YES', PAST 12-MONTH CONSUMERS WHO HAVE SOUGHT APPROVAL, 2021, N=2,703




# Medical authorization

In 2021, 1 in 5 past 12-month cannabis consumers reported 'ever' receiving approval for medical cannabis use.


## Have you ever received a recommendation for medical marijuana?

% 'YES', PAST 12-MONTH CONSUMERS, N=34,277



## Have you ever received a recommendation for medical marijuana?

% 'YES', PAST 12-MONTH CONSUMERS, 2021, N=10,472




# Medical authorization

In 2021, 14% of past 12-month cannabis consumers reported having a recommendation for medical cannabis use in the past year, a modest increase from 12% in 2018.


## Did you have a recommendation to use medical marijuana at any time in the past 12 months?

% 'YES', PAST 12 MONTH CONSUMERS, N=34,258



## Did you have a recommendation to use medical marijuana at any time in the past 12 months?

% 'YES', PAST 12-MONTH CONSUMERS, 2021, N=10,468




# Cannabis use to manage or improve mental health

'Ever' cannabis consumers reported using cannabis to improve or manage a range of mental health conditions, including anxiety, depression and PTSD.

## Have you ever used marijuana to improve or manage symptoms for any of the following?

% 'YES' AMONG 'EVER' CANNABIS CONSUMERS, 2021, N=20,125




# Cannabis use to manage or improve physical health

'Ever' cannabis consumers reported using cannabis to improve or manage a range of symptoms, including pain, sleeping problems and headaches/migraines.

## Have you ever used marijuana to improve or manage symptoms for any of the following?


% 'YES' AMONG 'EVER' CANNABIS CONSUMERS, 2021 N=20,125



# Types of cannabis products

## Cannabis consumers 2018–2021

Dried flower was the most commonly used product among past 12-month consumers in all years; however, the prevalence of dried flower use had a modest decrease between 2018 and 2021. Most other products increased between 2018 and 2021.






# Types of cannabis products 2021


Among past 12-month consumers, the prevalence of dried flower, edibles, drops/capsules, and vape oils were generally similar between illegal, medical, and illegal states.




## Dried herb




## Edibles



## Drops or capsules




## Vape oils




# Types of cannabis products 2021




## Hash or kief




## Topicals




## Solid concentrates



## Drinks



## Tinctures




# Use of 'non-THC' CBD products

In 2021, over 1 in 4 respondents from the US reported using "CBD-only products" (with no THC) in the past 12 months. The most common CBD product types were oil/liquid drops, topicals, and edibles.


## Use of CBD-only products

IN PAST 12 MONTHS N=29,927



## Type of CBD-only products used

AMONG THOSE WHO REPORTED CBD-ONLY PRODUCT USE, N=8,356






# 'Delta-8' THC products – Awareness

In 2021, 'Delta-8 THC' products were widely marketed in the US, particularly in jurisdictions in which conventional 'Delta 9 THC' products were illegal for adult use. Approximately 16% of US respondents reported hearing about Delta-8 products. Awareness levels for 'Delta-8' were somewhat higher than the levels for 'Delta-4' or 'Delta-10' products, which were included as 'bogus' options given that these products are not currently marketed or sold in the US. The results suggests higher levels of awareness for Delta-8 products, despite a certain level of misreporting due to confusion about THC types.

## Some new types of products contain DELTA-8 THC. Have you heard of products that contain the following?

% 'YES', ALL RESPONDENTS, 2021, n=30,081






# 'Delta-8' THC products – Use

In 2021, 27% of respondents who had heard of 'Delta-8' THC reported using a Delta-8 THC product in the past 30 days, corresponding to approximately 3% of all respondents in the US. These estimates should be interpreted with caution given the high likelihood of over-reporting due to confusion over 'Delta-8' products.


## Have you ever used a DELTA-8 THC product?

ALL RESPONDENTS, 2021, n=3,645

### Yes – In past 30 days



### Yes – more than 30 days ago






## 'Delta 8' THC products – Types

Among those that reported using 'Delta-8' THC products, dried herb, vapes, and edibles were the most commonly used, although these estimates are subject to wide confidence intervals due to low numbers of respondents reporting use.

### What type of DELTA-8 THC product have you used?

AMONG US RESPONDENTS THAT REPORTED AWARENESS AND USE OF DELTA-8 PRODUCTS, 2021, n=1,561




# Price of dried flower

Consumers in legal states reported paying an average of \$8.75 per gram of dried flower in 2021, including from legal and illegal sources. The price paid for dried flower from illegal and legal retail sources decreased between 2018 to 2019 and then increased from 2019 to 2021. In 2019, the average price paid from legal sources was \$8.21 per gram, \$1.03 higher than from illegal sources, compared to \$8.99 in 2021, \$0.51 higher than illegal sources.

## Price paid for dried flower

SALES WEIGHTED PRICE-PER-GRAM OF DRIED FLOWER AT LAST PURCHASE, LEGAL STATES ONLY, 2018-2021, n=9,700



AMONG CONSUMERS IN LEGAL STATES WHO PURCHASED DRIED HERB IN THE PAST 12 MONTHS. AVERAGE PRICE-PER-GRAM OF DRIED FLOWER ADJUSTED FOR THE QUANTITY PURCHASED; 2018: CO, WA, AK, OR, MA; 2019: CO, WA, AK, OR, MA; 2020: CO, WA, AK, OR, MA, IL; 2021: CO, WA, AK, OR, MA, IL, NJ.


# Price of dried flower

## 2021


In 2021, the price of dried flower reported by consumers in legal states was lower in comparison to illegal and medical states. Prices reflect cannabis purchased from all sources, including legal (where permitted) and illegal retail sources.

### Price of dried flower

SALES WEIGHTED PRICE-PER-GRAM OF DRIED FLOWER AT LAST PURCHASE



### Among 'legal' states 2021



\* STATES IN WHICH LEGAL RETAIL STORES HAVE YET TO OPEN




# Cannabis sources

Family or friends were the most common source of cannabis among past 12-month consumers across all years. In 2021, over half of consumers got their cannabis from family or friends.

## Cannabis sources in the past 12-months


AMONG PAST 12-MONTH CONSUMERS




# Cannabis sources

Past 12-month consumers from legal states were more likely to report sourcing cannabis from a store, and past 12-month consumers from illegal states were more likely to report sourcing cannabis from family/friends or a dealer.


## Store, co-op, or dispensary




## Family member or friend



## Dealer



## Made or grew my own




# Purchasing cannabis from 'legal' sources

Past 12-month consumers from legal states reported purchasing the highest percentage of cannabis from legal retail sources in 2021.

## Mean percentage of all cannabis products purchased in last 12-months from a legal retail source

AMONG PAST 12 MONTHS CONSUMERS, RESPONDENTS AGE: 21+






# Perceptions of legal cannabis


Past 12-month consumers were more likely than all respondents to perceive cannabis from 'legal' sources as more expensive, and less convenient to purchase. Fewer respondents perceived differences in the quality and safety of cannabis from legal versus illegal sources.

- Legal marijuana is 'lower quality'
- Legal marijuana is 'more expensive'
- Legal marijuana is 'less convenient to buy'
- Legal marijuana is 'less safe to use'
- Legal marijuana is 'less safe to buy'

### ALL RESPONDENTS




### PAST 12-MONTH CONSUMERS



# Reasons for purchasing from retail 'illegal' sources

Consumers who purchased cannabis from an illegal retail source reported a range of reasons for doing so. Higher price, not having a prescription got medical marijuana, and lower convenience were the most common reasons for purchasing cannabis from illegal sources in 2021






# Perceptions of cannabis access


Respondents from legal states reported a higher ease of getting cannabis, buying cannabis from a legal store, and buying cannabis from a legal online source, compared to respondents from illegal or medical states.

2018 2019 2020 2021


## Ease of getting cannabis



## Ease of buying cannabis from a legal store or dispensary



## Ease of buying cannabis from a legal online source




# COVID-19 impact on consumption


## 2020 and 2021

Approximately 1 in 3 past 12-month consumers in the US reported that the COVID-19 pandemic changed their cannabis use, with a greater percentage indicating an increase in consumption.

### Impact of COVID-19 pandemic on cannabis use



### Percent of consumers who 'used more' or 'started using' cannabis during the pandemic






# Cannabis advertising exposure

In 2021, almost half of respondents in the US reported noticing at least one type of cannabis advertising or promotion in the past 12 months – Respondents from legal states reported higher exposure than those from medical or illegal states.


## Noticing any cannabis ads and promotions

AT LEAST ONE LOCATION IN THE PAST 12 MONTHS



## Noticing any cannabis ads and promotions – 2021

AT LEAST ONE LOCATION IN THE PAST 12 MONTHS








# Cannabis advertising exposure 2021

Among US respondents in 2021, social media was the most common source of advertising and promotion, followed by websites/online and billboards/posters.

## Noticing cannabis ads in the past 12-months

BY MARKETING CHANNEL, 2021, N=30,081






# Cannabis advertising exposure 2021

For most marketing channels, respondents reported similar sources of seeing and hearing cannabis advertising. However, respondents living in 'legal' states reported higher levels of noticing billboards and advertising in retail settings, including inside and outside stores.

## Noticing cannabis ads in the past 12-months

BY MARKETING CHANNEL, 2021, N=30,081




AMONG ALL RESPONDENTS. PERCENT REPORTING SEEING MARIJUANA BEING ADVERTISED OR PROMOTED IN AT LEAST 1 LOCATION IN PAST 12 MONTHS.


# Education campaign exposure

In 2021, 1 in 3 respondents in the US recalled seeing an education campaign or public health message about cannabis in the past 12 months, with higher exposure among respondents from legal states.

## Recall of cannabis education campaigns IN THE PAST 12 MONTHS



## By jurisdiction 2021




AMONG ALL RESPONDENTS. PERCENT REPORTING SEEING AN EDUCATIONAL CAMPAIGN OR PUBLIC HEALTH MESSAGE ABOUT CANNABIS IN AT LEAST 1 LOCATION IN PAST 12 MONTHS.




# Health warnings on products

Around 15% of respondents in the US—and over 20% of past 12-month consumers—reported seeing health warnings on cannabis products in the past year, with higher exposure among respondents from legal states.


## Noticing cannabis health warnings on packages



### ALL RESPONDENTS



### PAST 12-MONTH CONSUMERS






# Problematic cannabis use

The World Health Organization's ASSIST tool assesses low, moderate or high risk of problematic cannabis use. Between 2018 and 2021, 'high risk' cannabis use has remained relatively stable between 7-9%.

## Risk of problematic cannabis use

WHO ASSIST SCORES, AMONG PAST 12-MONTH CONSUMERS  
N=30,679



# Problematic cannabis use


'High risk' cannabis use was similar between illegal, medical, and legal states. In 2021, 'high risk' cannabis use among past 12-month users was about 10%.

## Risk of problematic cannabis use


WHO ASSIST SCORES, AMONG PAST 12-MONTH CONSUMERS

— Low risk — Moderate risk — High risk


### Illegal states n=4,117



### Medical states n=6,074



### Legal states n=20,488





# Driving after cannabis use

The self-reported prevalence of driving within 2 hours of cannabis use in the US increased from 16% in 2018 to 21% in 2021.

## Driving a vehicle within 2 hours of cannabis use

IN THE PAST 12 MONTHS AMONG 'EVER' CANNABIS CONSUMERS,  
N=67,525






# Cannabis use at work


In 2021, 1 in 5 past 12-month cannabis consumers reported using cannabis within 2 hours of starting work. Prevalence of using cannabis at work was higher among consumers who reported working in hazardous jobs. Cannabis use at work decreased between 2018 and 2019, and then has remained relatively stable between 2019 and 2021.

## Cannabis use at work (including breaks) or within 2 hours of starting work in past 30 days


% 'YES', AMONG PAST 12-MONTH CANNABIS CONSUMERS, N=33,918




### Illegal states n=4,570



### Medical states n=6,681



### Legal states n=22,667



"IN THE PAST 30 DAYS, HAVE YOU USED MARIJUANA AT WORK (INCLUDING BREAKS) OR WITHIN 2 HOURS OF STARTING WORK?" AMONG PAST 12-MONTH CONSUMERS




# Adverse events from cannabis use

In 2021, approximately 9% of past 12-month cannabis consumers in the US reported seeking medical help for an adverse event from cannabis. Among those who sought medical help, emergency rooms and doctors or health professionals were the most common sources of help.


## Percentage of consumers who sought medical help for adverse effects caused by cannabis use

AMONG PAST 12-MONTH CONSUMERS, 2021 N=10,346



## Sources of assistance among consumers who sought medical help for adverse effects

AMONG THOSE WHO SOUGHT MEDICAL HELP




# Storage of cannabis in home

Almost 6 in 10 past 12-month consumers in the US stored cannabis in the home in a variety of locations.


## Do you currently keep any marijuana in or around your home?

% 'YES' PAST 12-MONTH CONSUMERS, 2021, N=10,154



## Where is the marijuana in your home stored?

% 'YES', AMONG CONSUMERS WHO STORED CANNABIS IN HOME, 2021, N=6,274




# Accidental ingestion

In 2021, around 10% of past 12-month consumers in the US reported at least one case of accidental cannabis consumption in the home. Accidental consumption was most commonly reported for respondents themselves or an adult, but included youth, children, and pets.


## In the past 12 months, has anyone in your household accidentally consumed marijuana?

% 'YES' PAST 12-MONTH CONSUMERS, 2021, N=33,999



## Who was it that accidentally consumed marijuana?

% AMONG RESPONDENTS REPORTING ACCIDENTAL INGESTION IN HOME, 2021




# Risk perceptions


Risk perceptions of smoking tobacco cigarettes were highest, followed by alcohol, with slightly higher risk perceptions for vaping versus smoking cannabis.

## In your opinion, what is the level of health risk from...


### Smoking cigarettes daily




### Drinking alcohol daily



### Smoking marijuana daily



### Vaping marijuana daily




# Risk perceptions


Among cannabis products, use of synthetic products was perceived as highest risk, followed by high-potency cannabis. Lower risk perceptions were reported for using edibles and exposure to second-hand cannabis smoke.

## In your opinion, what is the level of health risk from...


### Consuming edibles daily




### Using synthetic marijuana daily



### Using high-potency marijuana concentrates daily




### Exposure to second-hand marijuana smoke daily




# Risk perceptions

**In your opinion, what is the level of health risk from...**  
 % Moderate – High risk

## By sex



## By cannabis use




# Risk perceptions

## In your opinion, what is the level of health risk from...


% Moderate – High risk

— Illegal states — Medical states — Legal states


### Smoke cannabis




### Vape cannabis




### Consume edibles




### Use synthetic cannabis



### Use high-potency concentrates




### Exposure to second-hand cannabis smoke




# Social acceptability of cannabis

In 2021, over 1 in 3 respondents perceived general 'approval' for cannabis, with few changes since 2018.

**In your opinion, do people generally approve or disapprove of marijuana?**  
 % 'APPROVE' OR 'STRONGLY APPROVE'



## US overall 2021



AMONG ALL RESPONDENTS.




# Social acceptability of cannabis


Approximately 1 in 5 respondents would feel comfortable using cannabis in public.

## How comfortable or uncomfortable would you feel openly using marijuana in public?

% 'COMFORTABLE' OR 'VERY COMFORTABLE'



### US total 2021






# Support for cannabis legalization


In 2021, 6 in 10 US respondents supported legalization of non-medical cannabis, with approximately 2 in 10 opposed to legalization. Support has increased between 2018 and 2021 across 'illegal', 'medical', and 'legal' states.

## Recreational (non-medical) marijuana should be...


AMONG ALL RESPONDENTS, N=106,670




### Illegal states n=17,792



### Medical states n=24,494



### Legal states n=64,384



# Acknowledgements

## ICPS INVESTIGATORS

**David Hammond** Canada

**Samantha Goodman** Canada

**Elle Wadsworth** Canada

**Pete Driezen** Canada

**Julia Dilley** United States

**Tom Freeman** United Kingdom

**Wayne Hall** Australia

**Gary Chan** Australia

**Beau Kilmer** United States

**Rosalie Pacula** United States

**Gillian Schauer** United States

**Chris Wilkins** New Zealand

**Marta Rychert** New Zealand

## PROJECT STAFF

**Danielle Corsetti** Project Manager

**Maryam Iraniparast** Data Analyst

**Robin Burkhalter** Data Analyst

**Daniel Danh Hong** Research Assistant





Visit the study website for more information: [www.cannabisproject.ca](http://www.cannabisproject.ca).

**CONTACT**

DAVID HAMMOND PhD  
PROFESSOR  
SCHOOL OF PUBLIC HEALTH SCIENCES  
UNIVERSITY OF WATERLOO  
DHAMMOND@UWATERLOO.CA



UNIVERSITY OF  
**WATERLOO**

School of Public  
Health Sciences

